Marinomed Granted European Patent for Anti-Viral Active Ingredient

A core component of Marinomed’s respiratory technology platform

15-Mar-2010 - Austria

Marinomed Biotechnologie GmbH announced that it has been granted the European Patent No.2101792, entitled ‘Use of Carrageenan for treating rhinovirus infections’ by the European Patent Office.

Along with the antiviral polymer patent granted in April 2009, this patent covers a core component of Marinomed’s proprietory respiratory technology platform. Marinomed is using this platform to develop therapies that target more than 100 different respiratory virus strains. Respiratory viruses are responsible for some of the most common infectious diseases in humans such as the common cold and influenza. Specifically, this patent, which was granted in March 2010, protects the intellectual property for the active ingredient Carageenan.

Treatment options that are active against the majority of respiratory viruses are of particular importance for immunocompromised patients and patients suffering from COPD or asthma as common respiratory pathogens can exacerbate their conditions with severe consequences.

Based on this technology Marinomed has developed the first product – an antiviral nasal spray using Carageenan, which has marketing authorization in Europe. The benefits for patienst arising from products generated by this respiratory technology platform has been validated in clinical trials with adults and children. Marinomed intends to seek partners to market the nasal spray worldwide and to exploit the unique properties of the technology platform in additional products.

https://www.bionity.com/en/news/114828/marinomed-granted-european-patent-for-anti-viral-active-ingredient.html